Aridis to delist from Nasdaq; Bicycle closes $200M+ offering

Aridis Phar­ma­ceu­ti­cals is be­ing tak­en off the Nas­daq, ef­fec­tive Wednes­day.

The biotech re­port­ed the news in an SEC fil­ing Mon­day, say­ing that it will be delist­ed from the Nas­daq Cap­i­tal Mar­ket once the mar­ket opens on Ju­ly 19th and that its stock will be trad­ed on OTC Pink Sheets.

The delist­ing comes as the com­pa­ny an­nounced Mon­day af­ter­noon that it had re­ceived pos­i­tive feed­back from the EMA on run­ning a Phase III tri­al for its can­di­date AR-301, a mon­o­clon­al an­ti­body that it is de­vel­op­ing as an ad­junc­tive with stan­dard of care for a spe­cif­ic type of pneu­mo­nia. AR-301 failed a Phase III ear­li­er this year.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN